Ertapenem Injectable (Iv/Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV/IM)
Available Strengths: 1 g per vial for IV or IM use
Reference Brands: Invanz(US & EU)
Category:
Antibiotics
Ertapenem inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis and death. Its broad-spectrum activity includes resistant gram-negative bacteria. Benefits include rapid bacterial clearance, high tissue penetration, once-daily dosing, and effectiveness against serious infections like intra-abdominal infections and pneumonia in hospital settings.
Ertapenem Injectable (IV/IM) is available in Injectable (IV/IM)
and strengths such as 1 g per vial for IV or IM use.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ertapenem Injectable (IV/IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ertapenem Injectable (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ertapenem injectable is approved in the EU and US for treating complicated intra-abdominal infections, skin and soft tissue infections, and community-acquired pneumonia. In the EU, brands like Invanz are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA-approved formulations are based on extensive clinical data; generic versions are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans, for approval and ongoing safety monitoring. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access, ensuring adherence to European and US standards for safe, effective antibacterial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing